share_log

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

HC Wainwright & Co.以买入评级启动对Moleculin Biotech的报道,宣布目标股价为3美元
Benzinga ·  2023/12/14 06:06

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Moleculin Biotech (NASDAQ:MBRX) with a Buy rating and announces Price Target of $3.

HC Wainwright & Co. 分析师弗农·贝纳迪诺以买入评级开始报道Moleculin Biotech(纳斯达克股票代码:MBRX),并宣布目标股价为3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发